Natera executive chairman Matthew Rabinowitz sells $34.8m in stock

Matthew Rabinowitz, the Executive Chairman of Natera Inc. (NTRA), divested a substantial portion of his stake in the company. On September 14 and 15, 2026, he executed two batches of sales, selling a total of 101,000 shares valued at $34,797,270. The shares were traded at prices between $328.0942 and $351.245 per share. The sales occurred as Natera's stock hovered around $345.34, close to its 52-week high of $357.14, following a dramatic 97% increase over the previous year.

Analysts indicate that Natera is currently overvalued based on its Fair Value. Investors can delve deeper into the company’s performance through the Pro Research Report, which covers NTRA and over 1,400 other US equities. These transactions were executed under pre-arranged Rule 10b5-1 trading plans. On September 14, Rabinowitz sold 50,000 shares, and on September 15, he sold an additional 51,000 shares.

Out of the total, 99,000 shares were sold directly by him, while 2,000 shares were sold indirectly by his spouse under a separate Rule 10b5-1 trading plan. After these reported transactions, Rabinowitz still holds 2,125,394 shares of Natera common stock directly. Natera recently reported a revenue figure that surpassed Wall Street's expectations in its second quarter.

The company generated approximately $753 million, beating the forecasted $661.26 million. Management attributed this success to accelerated growth across its primary business areas, increased test volumes, improved margins, and several regulatory successes. The company has also revised its full-year revenue guidance, signaling continued robust performance.

Rothschild Redburn recently initiated coverage on Natera with a Buy rating and a price target of $385.00, highlighting the company's leadership in minimal residual disease testing with its Signatera tumor-informed test.